Consequently, the FDA successively approved Dato-DXd in 2025 for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor2 (HER2)-negative breast cancer and locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC. Here, ERBB2 is linked to breast cancer.